Zevra publishes Phase 2/3 pediatric substudy showing MIPLYFFA tolerability in infants with Niemann-Pick type C

Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc.

ZVRA

0.00
  • Zevra Therapeutics reported publication of positive Phase 2/3 open-label pediatric substudy results for MIPLYFFA in infants with Niemann-Pick disease type C.
  • Results have already been presented via the journal publication, not flagged for a future medical meeting.
  • The study found the therapy was generally well tolerated in very young children, with no new safety concerns versus older pediatric experience.
  • Pharmacokinetic findings aligned with prior pediatric data, supporting the case for evaluating earlier treatment initiation.
  • The data set was small, limiting conclusions on developmental outcomes despite signals consistent with disease variability.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zevra Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230730PRIMZONEFULLFEED9750829) on June 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.